These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34776964)

  • 41. Combinations of ketamine and atropine are neuroprotective and reduce neuroinflammation after a toxic status epilepticus in mice.
    Dhote F; Carpentier P; Barbier L; Peinnequin A; Baille V; Pernot F; Testylier G; Beaup C; Foquin A; Dorandeu F
    Toxicol Appl Pharmacol; 2012 Mar; 259(2):195-209. PubMed ID: 22245128
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors.
    Linge R; Jiménez-Sánchez L; Campa L; Pilar-Cuéllar F; Vidal R; Pazos A; Adell A; Díaz Á
    Neuropharmacology; 2016 Apr; 103():16-26. PubMed ID: 26711860
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors.
    Sartim AG; Guimarães FS; Joca SR
    Behav Brain Res; 2016 Apr; 303():218-27. PubMed ID: 26801828
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacological interaction of Galphimia glauca extract and natural galphimines with Ketamine and Haloperidol on different behavioral tests.
    Santillán-Urquiza MA; Herrera-Ruiz M; Zamilpa A; Jiménez-Ferrer E; Román-Ramos R; Tortoriello J
    Biomed Pharmacother; 2018 Jul; 103():879-888. PubMed ID: 29710504
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
    Espejo-Porras F; Fernández-Ruiz J; Pertwee RG; Mechoulam R; García C
    Neuropharmacology; 2013 Dec; 75():155-63. PubMed ID: 23924692
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice.
    Schiavon AP; Bonato JM; Milani H; Guimarães FS; Weffort de Oliveira RM
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():27-34. PubMed ID: 26187374
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug.
    Zuardi AW; Crippa JA; Hallak JE; Moreira FA; Guimarães FS
    Braz J Med Biol Res; 2006 Apr; 39(4):421-9. PubMed ID: 16612464
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sex-Specific Cannabidiol- and Iloperidone-Induced Neuronal Activity Changes in an In Vitro MAM Model System of Schizophrenia.
    Thériault RK; St-Denis M; Hewitt T; Khokhar JY; Lalonde J; Perreault ML
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073710
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors.
    Campos AC; Ferreira FR; Guimarães FS
    J Psychiatr Res; 2012 Nov; 46(11):1501-10. PubMed ID: 22979992
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of the Psychopharmacological Effects of Tiletamine and Ketamine in Rodents.
    Popik P; Hołuj M; Kos T; Nowak G; Librowski T; Sałat K
    Neurotox Res; 2017 Nov; 32(4):544-554. PubMed ID: 28577066
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia.
    Kandratavicius L; Balista PA; Wolf DC; Abrao J; Evora PR; Rodrigues AJ; Chaves C; Maia-de-Oliveira JP; Leite JP; Dursun SM; Baker GB; Guimaraes FS; Hallak JE
    BMC Neurosci; 2015 Mar; 16():9. PubMed ID: 25887360
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine.
    Pedrazzi JF; Issy AC; Gomes FV; Guimarães FS; Del-Bel EA
    Psychopharmacology (Berl); 2015 Aug; 232(16):3057-65. PubMed ID: 25943166
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nitroprusside single-dose prevents the psychosis-like behavior induced by ketamine in rats for up to one week.
    Maia-de-Oliveira JP; Lobão-Soares B; Ramalho T; Gavioli EC; Soares VP; Teixeira L; Baker GB; Dursun SM; Hallak JE
    Schizophr Res; 2015 Mar; 162(1-3):211-5. PubMed ID: 25586741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia.
    Levin R; Almeida V; Peres FF; Calzavara MB; da Silva ND; Suiama MA; Niigaki ST; Zuardi AW; Hallak JE; Crippa JA; Abílio VC
    Curr Pharm Des; 2012; 18(32):4960-5. PubMed ID: 22716146
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular determinants of behavioral changes induced by neonatal ketamine and dexmedetomidine application.
    Turktan M; Yilmaz MB; Hatipoglu Z; Ilgaz S; Barc ED; Oksuz H; Akillioglu K; Ozcengiz D
    J Neural Transm (Vienna); 2019 Dec; 126(12):1577-1588. PubMed ID: 31522257
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuronal injury, but not microglia activation, is associated with ketamine-induced experimental schizophrenic model in mice.
    Hou Y; Zhang H; Xie G; Cao X; Zhao Y; Liu Y; Mao Z; Yang J; Wu C
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():107-16. PubMed ID: 23603358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Chronic administration of synthetic cannabidiol induces antidepressant effects involving modulation of serotonin and noradrenaline levels in the hippocampus.
    Abame MA; He Y; Wu S; Xie Z; Zhang J; Gong X; Wu C; Shen J
    Neurosci Lett; 2021 Jan; 744():135594. PubMed ID: 33388355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Interactions between cannabidiol and Δ
    Todd SM; Zhou C; Clarke DJ; Chohan TW; Bahceci D; Arnold JC
    Eur Neuropsychopharmacol; 2017 Feb; 27(2):132-145. PubMed ID: 28043732
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Managing chronic whiplash associated pain with a combination of low-dose opioid (remifentanil) and NMDA-antagonist (ketamine).
    Lemming D; Sörensen J; Graven-Nielsen T; Lauber R; Arendt-Nielsen L; Gerdle B
    Eur J Pain; 2007 Oct; 11(7):719-32. PubMed ID: 17197214
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
    Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
    Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.